drugset / Trial / NCT05955170
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.
Timeline
- Start
- 2023-12-19
- Primary completion
- 2027-12-19
- Completion
- 2028-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | — | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Subcutaneous |
| Subject | Trastuzumab | Monoclonal antibody | 600 mg | Subcutaneous |
| Subject | Tucatinib | Small molecule | 300 mg | Oral |